

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0237

TITLE: Evaluation of Feasibility for a Case-Control Study of  
Adrenal Androgen Production in Postmenopausal Women  
with Breast Cancer

PRINCIPAL INVESTIGATOR: Joanne F. Dorgan, Ph.D.

CONTRACTING ORGANIZATION: Fox Chase Cancer Center  
Philadelphia, Pennsylvania 19111

REPORT DATE: July 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040922 045

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> July 2004	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Jul 03-30 Jun 04)	
<b>4. TITLE AND SUBTITLE</b> Evaluation of Feasibility for a Case-Control Study of Adrenal Androgen Production in Postmenopausal Women with Breast Cancer			<b>5. FUNDING NUMBERS</b> DAMD17-01-1-0237	
<b>6. AUTHOR(S)</b> Joanne F. Dorgan, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Fox Chase Cancer Center Philadelphia, Pennsylvania 19111  E-Mail: Joanne.Dorgan@fccc.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 Words)</b>  Background: Postmenopausal women with elevated serum estrogens and androgens are at an increased risk of breast cancer. Dehydroepiandrosterone sulfate (DHEAS) is secreted only by the adrenals, and elevated serum DHEAS levels in postmenopausal women who develop breast cancer suggest increased adrenal androgen production. Objective/Hypothesis: We will evaluate the feasibility of conducting a case-control study that uses adrenocorticotrophic hormone (ACTH) stimulation tests to determine if postmenopausal women who develop breast cancer secrete more adrenal androgens, which are converted to estrogens in peripheral tissues, in response to ACTH stimulation compared to unaffected women. Hypotheses to be tested in the full-scale study are: 1) greater adrenal responsiveness to ACTH contributes to elevated serum concentrations of androgens and estrogens in postmenopausal women who develop breast cancer; and 2) increased adrenal androgen production in postmenopausal women with breast cancer is related to increased enzyme activity at a specific step in steroidogenesis. Specific Aims: Specific aims of the feasibility study are: 1) determine the feasibility of a full-scale study; 2) gather preliminary data on basal and ACTH stimulated serum concentrations of dehydroepiandrosterone (DHEA), androstenedione, testosterone, estradiol, and estrone in women with breast cancer compared to controls. Study Design: A case-control study will be conducted at FCCC.				
<b>14. SUBJECT TERMS</b> ACTH			<b>15. NUMBER OF PAGES</b> 6	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

## Table of Contents

Front Cover .....	1
Standard Form 298 .....	2
Table of Contents .....	3
Introduction .....	4
Body .....	4
Key Research Accomplishments .....	6
Reportable Outcomes .....	6
Conclusions .....	6
References .....	6
Appendices .....	6

**Introduction:** Postmenopausal women with elevated serum estrogens and androgens are at an increased risk of breast cancer. Dehydroepiandrosterone sulfate (DHEAS) is secreted only by the adrenals, and elevated serum DHEAS levels in postmenopausal women who develop breast cancer suggest increased adrenal androgen production. The objective of the pilot study is to evaluate the feasibility of conducting a case-control study that uses adrenocorticotrophic hormone (ACTH) stimulation tests to determine if postmenopausal women who develop breast cancer secrete more adrenal androgens, which are converted to estrogens in peripheral tissues, in response to ACTH stimulation compared to unaffected women. Hypotheses to be tested in the full-scale study are: 1) greater adrenal responsiveness to ACTH contributes to elevated serum concentrations of androgens and estrogens in postmenopausal women who develop breast cancer; and 2) increased adrenal androgen production in postmenopausal women with breast cancer is related to increased enzyme activity at a specific step in steroidogenesis rather than to generalized enhancement of adrenal androgen production. Cellular immune function also has been hypothesized to play a role in breast cancer etiology, and cortisol, which is another hormone that is secreted by the adrenals, is immunosuppressive (i.e., causes significant decreases in numbers and percentages of lymphocytes in the blood). At no additional cost to DOD we are also collecting preliminary data to begin to address the hypothesis that greater adrenal responsiveness to ACTH contributes to greater immunosuppression in postmenopausal women who develop breast cancer.

**Body:** Research accomplishments are described for each task outlined in the approved statement of work.

*Task 1. Prepare for data collection, Month 1-2*

- a. *Finalize data collection protocol and forms.* This activity has been completed and all questionnaires have been approved by both the FCCC IRB and the DOD IRB.
- b. *Finalize database design and data entry screen.* This activity has been completed.
- c. *Hire and train study coordinator.* This activity has been completed.

*Task 2. Identify and recruit participants, Months 2-6*

- a. *Search FCCC Breast Evaluation Clinic and breast surgical consultation visit summaries each day to identify potential cases and benign breast disease controls.* The FCCC IRB required that we conduct the study in phases – recruiting and conducting dexamethasone suppression and ACTH stimulation studies on healthy controls during the first phase, on spouses of cancer patients during the second phase, and on women who had breast cancer during the third phase. A FCCC Data Safety and Monitoring Board and the DOD IRB will review results after each phase before we can proceed to the next phase. Because we are currently recruiting healthy controls for phase 1, via advertisements and posters that have been approved by the FCCC and DOD IRB's, this activity has not been initiated. Note that benign breast disease controls have been replaced by spouses of cancer patients to control for chronic psychological stress associated with being diagnosed with cancer or with a spouse being diagnosed with cancer. There also was concern that benign breast disease controls may not be appropriate because elevated hormone levels have been

associated with benign breast disease in some studies. This was approved in the original protocol submitted to the DOD.

- b. *Obtain physician approval to contact cases and benign breast disease controls.* For the reasons described above under (a), this activity has not been initiated.
- c. *Identify one friend control who is eligible and agrees to participate for each case:* Friend controls have been replaced with healthy community controls because of the IRBs concerns about asking cases to identify friends who did not have breast cancer. This was approved in the original protocol submitted to the DOD.
- d. *Perform approximately 60 telephone interviews.* As of June 10, 2004, 93 postmenopausal women responded to the advertisement and called Fox Chase for more information. Of these women, 46 were not eligible for participation based on the preliminary screening questionnaire approved by the FCCC and DOD IRBs. Eighteen women were not interested once they received more information about the study. We identified 16 women who are potentially eligible.
- e. *Send approximately 30 follow-up letters.* Letters have been sent to 29 people.

*Task 3. Conduct data collection visits, Months 2-8.* We received FCCC IRB and DOD IRB approval of changes to the protocol submitted in June 2003 before beginning data collection visits.

- a. *Administer 30 questionnaires.* Three questionnaires have been administered.
- b. *Measure heights and weights of 30 participants.* Heights and weights of 4 participants have been measured.
- c. *Perform 30 ACTH stimulation tests, collect and store serum specimens.* ACTH stimulation tests have been performed on 4 participants. The specimens are currently being stored at the FCCC biosample repository.
- d. *Extract DNA from lymphocytes for 30 participants and store.* DNA has been extracted from lymphocytes for 4 participants and is being stored at the FCCC biosample repository.
- e. *Key and verify data.* Data has been keyed and verified for 4 participants.

*Task 4. Create serum and plasma pools for laboratory quality control, Month 8.* This task will be done when we get closer to conducting laboratory analyses.

*Task 5. Measure the ACTH concentration in plasma and DHEAS, DHEA, androstenedione, testosterone, estradiol, concentrations in serum from 30 participants, Months 9-10.* This task will be done after conduct of dexamethasone suppression and ACTH stimulation studies. Note that the FCCC IRB required that we perform interim analyses of DHEA after each phase of the study before progressing to the next phase and obtain approval of the Data and Safety Monitoring Board before progressing to the next phase. The DOD IRB has required that they also review the results and approve before we proceed.

*Task 6. Analyze data and write reports, Months 11-12. This task will be completed in the future.*

- a. Perform statistical analyses
- b. Write final report
- c. Begin writing grant proposal for full scale study

**Key Research Accomplishments:**

- Our goal for the first phase of the study is to recruit 7 women.
- We have identified 16 women who are interested in participating and are potentially eligible.
- Four women have completed the study, as of June 10, 2004.
- One woman is scheduled to complete the study in June 2004.

**Reportable Outcomes:** None at this time.

**Conclusions:** This is an interim report for a pilot study. Based on our experience to date, it appears that we will be able to recruit healthy controls for a full scale case-control study that uses adrenocorticotrophic hormone (ACTH) stimulation tests to determine if postmenopausal women who develop breast cancer secrete more adrenal androgens, which are converted to estrogens in peripheral tissues, in response to ACTH stimulation compared to unaffected women. The full-scale study will also determine if greater adrenal responsiveness to ACTH contributes to greater immunosuppression in postmenopausal women who develop breast cancer. This is one of the first studies to examine, in an integrated approach, the interrelationships of hormonal and immune responses to adrenal suppression and stimulation in women with breast cancer in comparison to healthy controls. Identification of a role for the adrenals in the etiology of breast cancer in postmenopausal women could ultimately lead to detection of populations at an increased risk of breast cancer, provide an approach to screening for women at increased risk, and/or lead to chemopreventive strategies that target the responsible enzyme or regulatory protein.

**References:** None at this time.

**Appendices:** None at this time.